Indication
Suspicion of Alzheimers disease
This panel requires blood, plasma and CSF.
Clinical background
Alzheimer's Disease (AD) is a progressive neurological disease. AD is generally characterized by widespread deposition of amyloid beta (amyloid-β) plaques outside neurons and aggregation of abnormally phosphorylated tau proteins (p-tau) within neurons. These changes are associated with damage and loss of neurons in various parts of the brain. The biological mechanisms that lead to neuronal damage develop years before the onset of clinical symptoms.
Diagnosis entails a comprehensive examination including medical history, cognitive assessments, physical examination, neurological evaluation, analysis of biomarkers and genotyping.